NVRO News

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday. The St Helier, Jersey-based company now plans to raise $176 million by offering 7.5 million shares at a price range of $23 to $24. The company had previously filed to offer 12.5 million shares (5...read more

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, announced terms for its IPO on Monday. The St Helier, Jersey-based company plans to raise $344 million by offering 12.5 million shares (40% insider) at a price range of $26 to $29. At the midpoint of the proposed range, NovoCure would command a fully diluted market value of $2.6...read more

This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index slid another 6%. Despite these trends, IPO investors remain discerning: in addition to the postponed offerings, this week's...read more

Nevro, which is awaiting approval for an implanted electrical device that treats leg and back pain, raised $126 million by offering 7.0 million shares (vs. 6.25 million originally planned) at $18, above the $15 to $17 range. Nevro will list on the NYSE under the symbol NVRO. J.P. Morgan and Morgan Stanley acted as joint bookrunners on the deal....read more